The importance of achieving concentrations of both streptomycin and isoniazid adequate to sterilize all parent drug-susceptible organisms was empasized by in vitro studies on the prevention of emergence of mutants resistant to these drugs (1). Many factors determine the concentrations of these agents to which multiplying tubercle bacilli are exposed in the human subject: dosage; absorption and excretion; metabolic alteration; binding to protein; and diffusion into lesions, tissues and cells. Furthermore, with streptomycin the problem is complicated by the presence of substances in the lesions which antagonize the antibacterial action of the drug.
The importance of achieving concentrations of both streptomycin and isoniazid adequate to sterilize all parent drug-susceptible organisms was empasized by in vitro studies on the prevention of emergence of mutants resistant to these drugs (1) . Many factors determine the concentrations of these agents to which multiplying tubercle bacilli are exposed in the human subject: dosage; absorption and excretion; metabolic alteration; binding to protein; and diffusion into lesions, tissues and cells. Furthermore, with streptomycin the problem is complicated by the presence of substances in the lesions which antagonize the antibacterial action of the drug.
Metabolic alteration of isoniazid has been estimated from serum levels of antimicrobially-active drug collected at intervals following a test dose (2, 3) . Isoniazid is altered to derivatives such as acetyl-isoniazid and isonicotinic acid which have little or no antimicrobial activity (4, 5) . B6nicke and Reif (6), Cuthbertson, Ireland, Wolff and Kuper (7) , and Hughes, Schmidt and Biehl (8) have found that the rate of metabolic alteration of the isoniazid molecule varies widely in different individuals. Mandel, Cohn, Russell and Middlebrook (9) demonstrated a significant relationship between this rate of metabolic alteration of isoniazid and the bacteriologic response in isoniazid-treated tuberculous patients. The chemical methods thus far described for the determination of isoniazid (10) (11) (12) (13) (14) are not practical for the antimicrobially-active moiety, as they are neither sufficiently sensitive nor specific to permit measurement of the low concentrations present in the sera of many subjects receiving conventional dosages of this drug.
Streptomycin serum concentrations have been investigated, and apparently this drug is not subject to significant metabolic alteration (15) . There were differences between the serum concentrations of streptomycin achieved by four different subjects (16) . Most studies have tended to emphasize the uniformity of the handling of streptomycin from subject to subject (17) (18) (19) (20) .
However, very few human subjects were used. The purpose of this report (the second of a series) is to present our experiences with specific microbiologic assays for isoniazid and streptomycin performed on sera from isoniazid-and streptomycin-treated adult tuberculous patients, and to discuss the clinical significance of the results.
MATERIALS AND METHODS
Microbiologic assay for serum isoniazid was performed as previously described (2) . Isoniazid was given in total dosage of 8 to It should be noted that the microbiologic assay for isoniazid, originally described by Mandel and associates (2) , and employed here, differs significantly from other methods described in the literature (3, 21, 22) . Not only is it more specific for isoniazid by virtue of the fact that the end-point is determined by loss of acid-fastness 1 rather than by gross evidence of inhibition of growth, but it also requires a shorter period of time for its performance, i.e., five days versus the 10 days required for these other methods.
B. Serum isoniazid levels at six hours after a single loading dose. The initial microbiologic assay test was performed on 254 hospitalized adult tuberculous patients. C. Reproducibility of seruim level studies repeated on the samtxe individuals. Isoniazid serum level studies were repeated at least once on 163 patients. The interval between the first and subsequent studies was from one day to six months. The greatest number of such studies repeated on any one individual was five.
D. Effect of increasing the loading dose of isoniazid from 4 to 8 mg. per Kg. The effect of increasing the loading dose of isoniazid from 4 to 8 mg. per Kg. was 1Following the report that streptomycin administered first could prevent the isoniazid-produced loss of acidfastness, this was studied in the sera from some of our patients. The presence or absence of streptomycin in the serum did not alter the result of the microbiologic assay for isoniazid, because a streptomycin-resistant strain was employed.
studied in 54 patients whose initial serum levels had been 0.2 ,ug. or more of isoniazid per ml. of serum at six hours following a 4 mg. per Kg. test dose. E. Comparison of a "rapid" with a "slow" iniactivator of isoniazid by both chemical and microbiologic methods. Serum levels of antimicrobially-active isoniazid as well as isoniazid plus its derivatives were determined on serial specimens of sera from two patients: One achieved a lotw and the other a high level following the 4 mg. per Kg. test dose. The method of determination of isoniazid plus its derivatives was based on assay for isonicotinic acid after complete hydrolysis and oxidation, and was reported as isoniazid equivalent (10) . Blood was drawn for analysis at zero, two, four, six and 24 hours following an 8 mg. per Kg. test dose of isoniazid. The same study was repeated with 2.5 Gm. of para-aminosalicylic acid (2.85 Gm. NaPAS) added to the test dose of isoniazid. Para-aminosalicylic acid, 2.5 Gm., was also given at three, six and nine hours after the test dose.
F. Effect of variotus drugs on the scrumit isoniazid level. The effects of 13 different compounds on the antimicrobially-active serum isoniazid level were studied. Determinations were made on 160 serum specimens from 79 patients selected at random whose initial determinations revealed active serum levels below 0.4 ,ug. per ml. At the start of the drug testing program, the lowest dilution of serum employed was one to 10, but one to five dilutions were included later so that lower concentrations of isoniazid could be detected. All drugs except isoniazid were discontinued for at least one day prior to the test. On the test day, the patient usually was given a 4 mg. H. Microbiologic assay test for streptomycin. The concentration of streptomycin in sera was determined microbiologically by a filter-paper disc-seeded agar diffusion method similar to that described by Forgacs, Kornegay and Henley (23) . Bacto antibiotic medium 5 (Difco Laboratories, Inc., Detroit, Mich.), pH 8, was used as the test medium, and Bacillus subtilis "I" strain (obtained from the Army Medical Department, Research and Graduate School, Walter Reed Hospital, Washington, D.C.) was the test organism. An important modification of previously described filter-paper disc agar diffusion methods was employed in this study: The final seeded plate with test discs in place was stored at 40 C. for 48 hours before incubation at 360 C. This greatly improved the sensitivity and accuracy of the method and permitted the use of undiluted sera for impregnation of the filter-paper discs. It permitted estimation of streptomycin concentrations between 5 K. Correlation of in vitro druig resistantce with serumt streptomycin levels achieved by patients excreting resistant organtisms. The precise level of streptomycin resistance manifested by tubercle bacilli recovered from the sputum of 33 patients who were excreting organisms resistant to streptomycin on admission was studied quantitatively. The populations of tubercle bacilli from 16 of these patients were completely resistant to 2.0 ,ug. of streptomycin per ml., but less than 50 per cent were resistant to 10 Ag. of streptomycin per ml. It was considered possible that this low level of resistance might have resulted from failure of these 16 patients to achieve sufficiently high serum streptomycin levels during previous treatment with this drug. The streptomycin serum levels of these 33 patients at six hours after a 20 mg. per Kg. intramuscular loading dose of streptomycin were determined and correlated with the bacterial resistance findings. The results of the determinations of isoniazid plus all its derivatives in a "rapid" and a "slow" inactivator are presented in Figures 2 and 3 . It will be noted that at six hours after the loading dose of isoniazid approximately 56 per cent of the total serum isoniazid was in an antimicrobiallyactive form in the "slow" inactivator, whereas only 5 per cent was in this form in the "rapid" inactivator. Over the 24 hour period, the "slow" inactivator had approximately five times more antimicrobially-active drug in the serum, expressed as ug. hours per ml. of serum, than did the "rapid" inactivator.
F. Effect of various drugs on the isoniazid level
The effect of the drugs tested is presented in Tables I, II and III. The original observation on the effect of administration of para-aminosalicylic acid (PAS) on the metabolism of isoniazid in human subjects was reported elsewhere by us (2) . This observation has been confirmed by Morse and co-workers (3) and by Bell and Mitchell (22) . Dosages of para-aminosalicylic acid of 2.5 Gm. given at the zero and three hour times were more effective than the other dosage schedules studied.
The effects of para-aminosalicylic acid on the antimicrobially-active serum isoniazid level in a "rapid" and a "slow" inactivator have been shown It has been demonstrated that: 1) The addition of para-aminosalicylic acid (1,000 ,ug. per ml.) to the microbiologic assay medium does not modify the antimicrobial activity of isoniazid; 2) The addition of para-aminosalicylic acid to serum from patients receiving isoniazid does not alter the results of this test for antimicrobially-active isoniazid; and 3) The antimicrobial activity of isoniazid is not modified in vitro by serum (Table  III) from patients receiving large oral doses of para-aminosalicylic acid. Therefore, the method of microbiologic assay prevents the in vitro antimicrobial action of para-aminosalicylic acid.
It is clear ( Tables I and II ) that the addition of para-aminobenzoic acid which has no direct antimycobacterial action led to a detectable increase in the antimicrobially-active serum isoniazid level in the 71 subjects tested, and that this increase was generally higher and more sustained than that achieved by para-aminosalicylic acid. * Filter-paper disc -agar diffusion method using B. subtilis.
deviation from the mean of the results of the two studies was + 12 per cent. All patients had levels between 5 and 48 KIg. streptomycin per ml. of serum at six hours after the 20 mg. per Kg. of body weight dosage.
K. Correlation of in vitro drug resistance with serum streptomycin levels achieved by patients excreting resistant organisms
The results of this study are presented in Table  V . Statistical analysis of the difference between the two groups shows that it is highly significant (p < 0.01). The studies described here comparing the antimicrobially-active isoniazid level of serum with that of cavity content provide evidence that the serum level can be used fairly as a basis for estimating the concentration of isoniazid delivered to the multiplying bacilli in cavities. They also show that there is no important physicochemical barrier which interferes with the movement of antimicrobially-active isoniazid through cavity walls.
The results of previous studies have shown (9, 25) that the dosage of isoniazid which avoids the emergence of catalase-positive, weakly isoniazidresistant mutants is one which provides an antimicrobially-active isoniazid serum level of at least 0.4 ,ug. per ml. at six hours following one-half of the total daily dose. As previously indicated (1), this dosage yields drug levels in vivo which are much higher than necessary to avoid the emergence of any drug-resistant mutants when a second drug is employed, such as streptomycin, also in adequate dosage on combined drug treatment. Therefore, an optimal chemotherapeutic response may be anticipated (and with a wide margin of safety) in original treatment patients excreting drug-susceptible populations of tubercle bacilli if one-half of the total daily dose of isoniazid gives a serum level of at least 0.4 Mug. per ml.
An increase in the level of antimicrobially-active drug to insure that all patients will maintain adequate serum levels of isoniazid may be accomplished either by increasing the dosage of isoniazid or by employing drugs which apparently prevent rapid inactivation of the drug. An increase in dosage of isoniazid to 16 to 24 mg. per Kg. daily without pyridoxine has led to a prohibitive increase in isoniazid neuropathy (24) . The simultaneous administration of pyridoxine with isoniazid has reduced but not completely prevented toxicity due to isoniazid (24, 26) . Some few subjects inactivate isoniazid so rapidly that dosages of 16 to 20 mg. per Kg. per day are insufficient to maintain adequate, antimicrobially-active, serum isoniazid levels. It is in these patients that high dosage plus the concomitant administration of drugs such as paraaminosalicylic acid or para-aminobenzoic acid may be employed. A decrease in the rate of metabolic alteration of isoniazid by these drugs has been attributed to competition for the biochemical proc-ess of acetylation (27, 28) . The action of paraaminosalicylic acid on the antimicrobially-active serum isoniazid level suggests that the effectiveness of combined therapy employing isoniazid and para-aminosalicylic acid (29) is due not only to the antimicrobial activity of each drug, but also to the resulting elevation of the antimicrobially-active serum isoniazid level.
It seems fair to conclude that to achieve optimal therapeutic results and to reduce the incidence and severity of the toxic effects of the drug, serum levels of antimicrobially-active isoniazid should be known. The dosage of isoniazid which should be employed is clearly related to the rate at which the patient inactivates the drug; and it would seem that this can be measured satisfactorily by the microbiologic assay method.
While streptomycin does not appear to be subject to metabolic alteration in man (15) , the problem of adequate delivery of the drug to multiplying tubercle bacilli is very complicated (30) . Not all intramuscular injections (as routinely administered) are actually into muscle tissue. Absorption from such an "intramuscular" depot is influenced by factors such as inflammatory response and blood supply. Some subjects excrete streptomycin more rapidly than others. All other factors being equal (which they seldom are), heavy subjects should achieve relatively lower tissue concentrations than light subjects on a conventional 1.0 Gm. dosage schedule. There are also chemical components of inflammatory or necrotic tissue, such as nucleic acids, which antagonize the antimicrobial action of streptomycin (31) (32) (33) . Finally, the activity of streptomycin is modified by the concentration of viable tubercle bacilli exposed to it. Such uncontrollable variables render hazardous any attempt to correlate the concentration of streptomycin achieved in the serum with the actual delivery of the drug in an active form to tubercle bacilli in patients.
In spite of the uncontrollable modifying factors, it was considered important to know that at least the first step in the delivery of sufficient concentrations of streptomycin had been achieved. Accordingly, serum levels of antimicrobially-active streptomycin sulfate were determined. These confirmed previous reports that variations do exist between subjects (16, 34) .
The results of the studies which relate the levels of drug resistance of streptomycin-resistant mutants excreted by patients previously treated with streptomycin and the concentrations of streptomycin which are found in their sera after the standard test are significant. As in previous similar studies with isoniazid (9), these observations establish the six hour serum assay for streptomycin as a reliable basis for estimating the concentration of this drug delivered to multiplying tubercle bacilli in most patients. Thus, in spite of the indeterminable local factors which influence the antimicrobial activity of streptomycin, humoral levels of the drug play an important role.
SUMMARY
The results of microbiologic assays for antimicrobially-active isoniazid in serum and tuberculous cavity content are presented. Some effects of change in dosage of isoniazid and of concomitant administration of various other drugs on the antimicrobially-active serum isoniazid levels in patients are reported. Para-aminosalicylic acid and para-aminobenzoic acid were the only drugs studied that significantly increased this level.
The results of application of a microbiologic assay method for serum streptomycin are also presented, and, as previously shown for isoniazid, a significant relationship is demonstrated between serum levels of streptomycin and certain aspects of the microbiologic response in patients to streptomycin treatment.
The clinical implications of the variations in antimicrobially-active serum levels of both isoniazid and streptomycin achieved by different patients are discussed.
